一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Pomalidomide Impurity 57
Pomalidomide Impurity 57
  • Pomalidomide Impurity 57
  • Pomalidomide Impurity 57
  • Pomalidomide Impurity 57
  • Pomalidomide Impurity 57
  • Pomalidomide Impurity 57

Pomalidomide Impurity 57 NEW

Price Get Latest Price
Package 10mg 50mg 100mg
Min. Order: 10mg
Supply Ability: 1000
Update Time: 2025-12-16

Product Details

Product Name: Pomalidomide Impurity 57 CAS No.: 64552-20-1
Min. Order: 10mg Purity: 99%+ HPLC
Supply Ability: 1000 Release date: 2025/12/16
Molecular formula: C14H14N2O5

Pomalidomide Impurity 57;64552-20-1

Article illustration

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com


  • Product Information

  • Product Number: P059057

  • English Name: Pomalidomide Impurity 57

  • English Alias: methyl 5-amino-4-(1,3-dioxoisoindolin-2-yl)-5-oxopentanoate

  • CAS Number: 19143-28-3

  • Molecular Formula: C??H??N?O?

  • Molecular Weight: 290.27

  • Advantages

  • As an impurity reference standard for pomalidomide, this compound has the following advantages:

  • Well-defined structure and high stability, enabling precise analysis of side reaction mechanisms during pomalidomide synthesis, such as esterification, amino group introduction, and isoindoline ring construction, to optimize processes and reduce impurity generation;

  • The structure containing ester, amino, and isoindolinedione groups provides a standard substance for detection methods like HPLC and LC-MS, improving the separation and quantitative accuracy of complex-structured impurities;

  • Helps study the impact of ester and amino groups on drug stability and toxicological properties to provide a scientific basis for impurity control strategies.

  • Applications

  • Drug Development: Used as an impurity reference standard to identify and quantify Impurity 57 in pomalidomide preparations, evaluating the purity of APIs and formulations;

  • Quality Control: Acting as a standard substance to validate the sensitivity and specificity of detection methods (e.g., HPLC, LC-MS), ensuring impurity content meets pharmacopoeia requirements during production;

  • Stability Studies: Investigating the degradation behavior of this impurity under light, high temperature, and high humidity conditions to evaluate its impact on pomalidomide formulation stability.

  • Background Description

  • Pomalidomide is an immunomodulatory agent for treating multiple myeloma. In its synthesis, incomplete esterification reactions or raw material residues easily generate impurities such as methyl 5-amino-4-(1,3-dioxoisoindolin-2-yl)-5-oxopentanoate. Such impurities may affect drug safety and effectiveness, making research on them a key part of pomalidomide quality control.
  • Research Status

  • Current research focuses on:

  • Detection Method Optimization: Establishing trace detection methods (detection limits reach ppb level) using ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS);

  • Synthesis Process Improvement: Reducing impurity generation by optimizing reaction temperature and catalyst types;

  • Toxicological Evaluation: Studying the potential toxicity of this impurity through in vitro cell experiments and animal models;

  • Crystal Form Research: Analyzing the impact of impurity crystal forms on drug formulation stability to improve the quality control system.

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com




Company Profile Introduction

-

You may like

Recommended supplier

Product name Price   Suppliers Update time
VIP3Y
ShenZhen H&D Pharmaceutical Technology Co., LTD
2026-03-12
$52.00
VIP6Y
TargetMol Chemicals Inc.
2026-05-26
VIP6Y
RongNa Biotechnology Co.,Ltd
2026-06-30
INQUIRY
古田县| 新疆| 瑞丽市| 景泰县| 股票| 遂宁市| 基隆市| 林甸县| 洪湖市| 拜城县| 台江县| 澳门| 潢川县| 浮梁县| 乌兰县| 玛纳斯县| 天祝| 册亨县| 宜春市| 建德市| 营口市| 伊金霍洛旗| 万载县| 来宾市| 临清市| 南宫市| 昌都县| 临泉县| 景泰县| 奇台县| 贺兰县| 德阳市| 永和县| 高青县| 梅州市| 二连浩特市| 章丘市| 贵阳市| 余姚市| 丹凤县| 辽阳市|